Brief: Topline Results From Phase 2 Celia Study Of Diranersen,First Study To Show Reduction In Tau Pathology And Cognitive Benefit In Patients With Early Alzheimer'S Disease

Biogen

14/05/2026 12:02

May 14 (Reuters) - Biogen Inc BIIB.O:

TOPLINE RESULTS FROM PHASE 2 CELIA STUDY OF DIRANERSEN (BIIB080): FIRST STUDY TO SHOW REDUCTION IN TAU PATHOLOGY AND COGNITIVE BENEFIT IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

BIOGEN - DIRANERSEN SHOWS ROBUST REDUCTION IN TAU PATHOLOGY ACROSS ALL DOSES IN PHASE 2 CELIA STUDY

BIOGEN - DIRANERSEN SAFETY PROFILE CONSISTENT WITH PHASE 1B STUDY IN PHASE 2 CELIA RESULTS

BIOGEN - DIRANERSEN DEMONSTRATES SLOWING OF CLINICAL DECLINE ACROSS ALL DOSES IN PHASE 2 CELIA STUDY

BIOGEN - CELIA STUDY DID NOT MEET PRIMARY ENDPOINT FOR DOSE RESPONSE ON CDR-SB AT WEEK 76

BIOGEN: SAFETY AND TOLERABILITY PROFILE OF DIRANERSEN WAS GENERALLY CONSISTENT WITH PHASE 1B STUDY

Source text: ID:nGNX5CGhsZ

Further company coverage: BIIB.O

 ((Reuters.Briefs@thomsonreuters.com;))